- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06686394
Studio su Patritumab Deruxtecan con altri agenti antitumorali in partecipanti con cancro al seno HER2 positivo che si è diffuso e non può essere rimosso chirurgicamente (MK-1022-009)
HERTHENA-Breast-01: Uno studio di fase 1b/2, multicentrico, in aperto, di determinazione della dose per valutare la sicurezza e l'attività antitumorale di Patritumab Deruxtecan in partecipanti con cancro al seno HER2 positivo non resecabile localmente avanzato o cancro al seno metastatico
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn:
- About the safety and how well people tolerate of patritumab deruxtecan
- How many people have the cancer respond (get smaller or go away) to treatment
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
The following countries will be participating in the trial: Canada, United Kingdom, Israel, Japan, South Korea, and USA.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Toll Free Number
- Numero di telefono: 1-888-577-8839
- Email: Trialsites@msd.com
Luoghi di studio
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 2V7
- Reclutamento
- Kingston General Hospital ( Site 0061)
-
Contatto:
- Study Coordinator
- Numero di telefono: 6135336541
-
Toronto, Ontario, Canada, M5G 2M9
- Reclutamento
- Princess Margaret Cancer Centre ( Site 0001)
-
Contatto:
- Study Coordinator
- Numero di telefono: 416-946-4501
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Reclutamento
- Jewish General Hospital ( Site 0003)
-
Contatto:
- Study Coordinator
- Numero di telefono: 514-340-8222
-
Montreal, Quebec, Canada, H2X 3E4
- Reclutamento
- Centre Hospitalier de l'Université de Montréal ( Site 0004)
-
Contatto:
- Study Coordinator
- Numero di telefono: (514)890-8000 x20737
-
-
-
-
-
Seoul, Corea del Sud, 03080
- Reclutamento
- Seoul National University Hospital ( Site 0030)
-
Contatto:
- Study Coordinator
- Numero di telefono: 82-2-2072-0850
-
Seoul, Corea del Sud, 05505
- Reclutamento
- Asan Medical Center ( Site 0031)
-
Contatto:
- Study Coordinator
- Numero di telefono: +82-2-1688-7575
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Giappone, 467-8602
- Reclutamento
- Nagoya City University Hospital ( Site 0020)
-
Contatto:
- Study Coordinator
- Numero di telefono: +81-52-851-5511
-
-
-
-
-
Haifa, Israele, 3109601
- Reclutamento
- Rambam Health Care Campus ( Site 0011)
-
Contatto:
- Study Coordinator
- Numero di telefono: 04-7776234
-
Petah Tikva, Israele, 4941492
- Reclutamento
- Rabin Medical Center ( Site 0012)
-
Contatto:
- Study Coordinator
- Numero di telefono: +972-505533121
-
Ramat Gan, Israele, 5265601
- Reclutamento
- Sheba Medical Center ( Site 0010)
-
Contatto:
- Study Coordinator
- Numero di telefono: 03-5304498
-
-
-
-
Camden
-
London, Camden, Regno Unito, NW1 2PG
- Reclutamento
- University College London Hospital ( Site 0041)
-
Contatto:
- Study Coordinator
- Numero di telefono: +442034472930
-
-
Glasgow City
-
Glasgow, Glasgow City, Regno Unito, G12 0YN
- Reclutamento
- The Beatson West of Scotland Cancer Centre ( Site 0043)
-
Contatto:
- Study Coordinator
- Numero di telefono: +441413017000
-
-
London, City of
-
London, London, City of, Regno Unito, EC1A 7BE
- Reclutamento
- St Bartholomew s Hospital ( Site 0040)
-
Contatto:
- Study Coordinator
- Numero di telefono: +442073777000
-
-
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Reclutamento
- University of Colorado Anschutz Medical Campus ( Site 0057)
-
Contatto:
- Study Coordinator
- Numero di telefono: 720-848-1030
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Reclutamento
- Dana-Farber Cancer Institute ( Site 0050)
-
Contatto:
- Study Coordinator
- Numero di telefono: 877-338-7425
-
-
New Jersey
-
New Brunswick, New Jersey, Stati Uniti, 08901
- Reclutamento
- Rutgers Cancer Institute of New Jersey ( Site 0052)
-
Contatto:
- Study Coordinator
- Numero di telefono: 732-235-2465
-
-
South Carolina
-
Greenville, South Carolina, Stati Uniti, 29605
- Reclutamento
- Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)
-
Contatto:
- Study Coordinator
- Numero di telefono: 864-455-3600
-
-
Virginia
-
Fairfax, Virginia, Stati Uniti, 22031
- Reclutamento
- Inova Schar Cancer Institute ( Site 0051)
-
Contatto:
- Study Coordinator
- Numero di telefono: 571-472-4724
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically confirmed HER2+ locally advanced unresectable breast cancer or metastatic breast cancer
- Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable hepatitis B virus (HBV) viral load before allocation
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 7 days before start of study intervention
Part 1 Arm 1:
- Has received at least a minimum of 2 and a maximum of 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
- Had disease progression on or after any previous trastuzumab deruxtecan (T-DXd) treatment
Part 1 Arm 2:
-Has received no more than 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
Part 1 Arm 3:
-Has received and had disease progression from T-DXd treatment in any setting and a maximum of 3 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting. T-DXd must be the most recent therapy received before enrollment.
Part 2 : Has not received prior systemic therapy (including T-DXd) for recurrent locally advanced or metastatic breast cancer (mBC).
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Uncontrolled or significant cardiovascular disease
- Has any history of (noninfectious) interstitial lung disease (ILD)/ pneumonitis irrespective of steroid use or has current ILD or suspected ILD
- Has clinically severe respiratory compromise
- Has any history of or evidence of any current leptomeningeal disease
- Has clinically significant corneal disease
- Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
- HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Part 1: Evidence of spinal cord compression or brain metastases
- Part 2: Evidence of spinal cord compression or brain/CNS metastases.
- Has an active infection requiring systemic therapy
- Concurrent active HBV and HCV infection
- Has had major surgical procedure (excluding placement of vascular access) less than 28 days
Part1: Arm 3 ONLY
- Has received prior treatment with tucatinib, lapatinib, or neratinib, or any investigational HER2-targeted tyrosine kinase inhibitors in the locally advanced or metastatic setting
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Part 1: Patritumab deruxtecan plus trastuzumab
Participants receive patritumab deruxtecan intravenous (IV) infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Altri nomi:
Trastuzumab administered via IV infusion
Altri nomi:
Trastuzumab biosimilar administered via IV infusion
Altri nomi:
|
|
Sperimentale: Part 1: Patritumab deruxtecan plus pertuzumab and trastuzumab
Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Altri nomi:
Trastuzumab administered via IV infusion
Altri nomi:
Trastuzumab biosimilar administered via IV infusion
Altri nomi:
Pertuzumab administered via IV infusion |
|
Sperimentale: Part 1: Patritumab deruxtecan plus trastuzumab and tucatinib
Participants receive patritumab deruxtecan IV infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks), and tucatinib is administered orally twice daily for each 21-day cycle, until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Altri nomi:
Trastuzumab administered via IV infusion
Altri nomi:
Trastuzumab biosimilar administered via IV infusion
Altri nomi:
Tucatinib administered as oral tablets |
|
Sperimentale: Part 2: Patritumab deruxtecan plus pertuzumab and trastuzumab
Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Altri nomi:
Trastuzumab administered via IV infusion
Altri nomi:
Trastuzumab biosimilar administered via IV infusion
Altri nomi:
Pertuzumab administered via IV infusion |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Part 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
Lasso di tempo: Up to 21 days
|
DLT will be defined as any drug-related AE observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle. The number of participants who experience a DLT will be presented. |
Up to 21 days
|
|
Part 1: Number of Participants with One or More Adverse Events (AEs)
Lasso di tempo: Up to approximately 36 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 36 months
|
|
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Lasso di tempo: Up to approximately 12 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be presented. |
Up to approximately 12 months
|
|
Part 2: Objective Response Rate (ORR)
Lasso di tempo: Up to approximately 36 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR)will be presented. |
Up to approximately 36 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Antibody-Drug Conjugate (ADC)
Lasso di tempo: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan ADC
Lasso di tempo: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan ADC
Lasso di tempo: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Maximum Plasma Concentration (Cmax) of Total Patritumab Deruxtecan Antidrug Antibody (ADA)
Lasso di tempo: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Total Patritumab Deruxtecan ADA
Lasso di tempo: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Total Patritumab Deruxtecan ADA
Lasso di tempo: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Free Payload
Lasso di tempo: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan Free Payload
Lasso di tempo: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan Free Payload
Lasso di tempo: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 2: Duration of Response (DOR)
Lasso di tempo: Up to approximately 36 months
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is alsoc onsidered PD. DOR as assessed by BICR will be presented. |
Up to approximately 36 months
|
|
Part 2: Progression Free Survival (PFS)
Lasso di tempo: Up to approximately 36 months
|
PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD)or death due to any cause, whichever occurs first as assessed by BICR. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented. |
Up to approximately 36 months
|
|
Part 2: Number of Participants with One or More AEs
Lasso di tempo: Up to approximately 36 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 36 months
|
|
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Lasso di tempo: Up to approximately 12 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 12 months
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Direttore dello studio: Medical Director, Merck Sharp & Dohme LLC
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie della pelle
- Malattie del seno
- Malattie della pelle e del tessuto connettivo
- Neoplasie mammarie
- Aminoacidi, peptidi e proteine
- Proteine
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Trastuzumab
- pertuzumab
- Tucatinib
- Patritumab Deruxtecan
- Ogivri
- Ontruzant
Altri numeri di identificazione dello studio
- 1022-009
- MK-1022-009 (Altro identificatore: MSD)
- jRCT2041250022 (Identificatore di registro: Japan Registry of Clinical Trials (jRCT))
- 2026-528266-19 (Identificatore di registro: EU CT)
- U1111-1346-4321 (Identificatore di registro: UTN)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .